Abstract:Due to their roles in inflammation, the sPLA2 enzymes are of much medicinal interest. sPLA2 inhibitors have been developed for the treatment of inflammatory and other conditions such as cardiovascular disease, arteriosclerosis and rheumatoid arthritis. To aid the medicinal chemist in the design of sPLA2 inhibitors, this review selected four human sPLA2s and presented the characteristics of the bound inhibitors that are considered key for high‐affinity interaction. The secreted phospholipase A2 (sPLA2) family of enzymes hydrolyzes glycerophospholipid substrates at the sn‐2 position of the acyl ester bond. Besides their roles in the degradation of phospholipids, these enzymes also play an important role in the immune response by promoting inflammation. The products of sPLA2‐catalysis (lysophospholipids and free fatty acids such as arachidonic acid) as well as secondary metabolites produced by the arachidonic acid cascade are mediators of inflammation and subsequent tissue injury. Based on their physiological functions, the sPLA2 enzymes are pharmacological targets for the treatment of diseases with an inflammatory component such as atherosclerosis and rheumatoid arthritis. Interestingly, sPLA2s may also have roles in various types of cancer such as malignant prostate cancer. While a number of sPLA2 inhibitors have been described, compounds which have been co‐crystallized with human sPLA2 enzymes are of much importance as such three‐dimensional structures provide valuable information regarding the structural requirements of good potency inhibitors as well as the molecular interactions between the enzyme and inhibitor. This review selected four structures of human sPLA2s complexed with inhibitors from the Protein Data Bank to illustrate the important molecular interactions of inhibitor compounds with the enzymes and to highlight the structural features important for interaction with the sPLA2 active site. In addition, the complex of the sPLA2 inhibitor, varespladib, with a Lys49‐PLA2‐like snake venom toxin is also discussed. Knowledge of the molecular interactions acquired from such structures would greatly aid the discovery of small molecule inhibitors of sPLA2s for the treatment of snakebite envenoming. The three‐dimensional structures presented in this review have been published by various research groups and have been deposited in the Protein Data Bank.

The research progress of cobra venom secretory phospholipase A2

Structure and Function of Snake Venom Secretory Phospholipase A_2

Unraveling snake venom phospholipase A2: an overview of its structure, pharmacology, and inhibitors

Purification of the phospholipase A_2 from Chinese cobra venom

Research Advances in the Molecular Mechanism of Snake Presynaptic Phospholipase A2 Neurotoxins

Emerging anticancer potential and mechanisms of snake venom toxins: A review

Discovery of Natural-pan Inhibitors by Targeting Snake Venom Secretory Phospholipase A2 through Computational Approaches

PLA2 inhibitors of snake serum

Proteomic diversity of Russell's viper venom: exploring PLA2 isoforms, pharmacological effects, and inhibitory approaches

Advances on the Relationship of Structure and Function of Snake Venom Serine Proteinases

Molecular Characterization of Three Novel Phospholipase A2 Proteins from the Venom of Atheris chlorechis, Atheris nitschei and Atheris squamigera

Crystal Structures of an Acidic Phospholipase A(2) from the Venom of Naja Kaouthia.

Electrospray Ionization Mass Spectrometry As A Critical Tool For Revealing New Properties Of Snake Venom Phospholipase A(2)

Varespladib Inhibits the Phospholipase A2 and Coagulopathic Activities of Venom Components from Hemotoxic Snakes

Computer-aided drug design of novel PLA2 inhibitor candidates for treatment of snakebite

Viper Venom Phospholipase A2 Database: The Structural and Functional Anatomy of a Primary Toxin in Envenomation

Interactions of small molecule inhibitors with secreted phospholipase A2: A review of the structural data

Research Progress on Group-XII Secreted Phospholipase A_2

Structure of A King Cobra Phospholipase A(2) Determined from A Hemihedrally Twinned Crystal

Crystal Structure of Phospholipase PA2-Vb, a Protease-Activated Receptor Agonist from the Trimeresurus Stejnegeri Snake Venom.

Molecular Characterization of Three Novel Phospholipase A₂ Proteins from the Venom of Atheris chlorechis, Atheris nitschei and Atheris squamigera